Movatterモバイル変換


[0]ホーム

URL:


CN106938996B - A kind of preparation method of Atorvastatin calcium intermediate - Google Patents

A kind of preparation method of Atorvastatin calcium intermediate
Download PDF

Info

Publication number
CN106938996B
CN106938996BCN201610004301.0ACN201610004301ACN106938996BCN 106938996 BCN106938996 BCN 106938996BCN 201610004301 ACN201610004301 ACN 201610004301ACN 106938996 BCN106938996 BCN 106938996B
Authority
CN
China
Prior art keywords
atorvastatin calcium
preparation
mixed solvent
added
amine ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610004301.0A
Other languages
Chinese (zh)
Other versions
CN106938996A (en
Inventor
吕伟
张忠理
吕兰亭
徐鹤
郭婷婷
李青丽
张新成
陈金春
马珍珍
王文
年蓓蕾
刘建国
马占坡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANFANG PHARMACEUTICAL CO Ltd
Original Assignee
TIANFANG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIANFANG PHARMACEUTICAL CO LtdfiledCriticalTIANFANG PHARMACEUTICAL CO Ltd
Priority to CN201610004301.0ApriorityCriticalpatent/CN106938996B/en
Publication of CN106938996ApublicationCriticalpatent/CN106938996A/en
Application grantedgrantedCritical
Publication of CN106938996BpublicationCriticalpatent/CN106938996B/en
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Classifications

Landscapes

Abstract

The present invention relates to a kind of preparation methods of Atorvastatin calcium intermediate, the preparation method while improving Atorvastatin calcium intermediate yield, the post-processing approach of Atorvastatin calcium intermediate is simple, operating process is simplified, the production cycle shorten, organic solvent consumption reduce, production cost reduce, production operation when risk reduce.Method includes the following steps: 1) react using amine ester and diketone as starting material in the mixed solvent, the mixed solvent is the normal heptane and tetrahydrofuran of volume ratio 1:1-3, every that 5-8ml mixed solvent is added using 1g amine ester;2) 1 gained reaction solution of concentration step removes mixed solvent, obtains Atorvastatin calcium crude intermediate;3) after the dissolution clarification of 1 ethyl alcohol of recrystallisation solvent being added in step 2 products therefrom, 2 purified water of recrystallisation solvent is added, is cooled down, centrifugal drying.

Description

A kind of preparation method of Atorvastatin calcium intermediate
Technical field
The present invention relates to a kind of preparation method of Atorvastatin calcium intermediate, in particular to a kind of post-processing step is simpleHigh purity atorvastatin calcium intermediate preparation method.
Background technique
Atorvastatin calcium, English name: Atorvastatin Calcium, chemical name: [R- (R, R)] -2- (4- fluorinePhenyl)-β, beta-dihydroxy -5- (1- Methylethyl) -3- phenyl -4- [(aniline) carbonyl] -1- hydrogen-three water of pyrroles's -1- enanthic acid calciumObject is closed, is Gao Hecheng, High Purity, the highly selective drug for inhibiting HMG-CoA reductase, is developed by Pfizer, be theThree generations's statins.It is mainly used for treating the prevention and treatment of hypercholesterolemia, hyperlipidemia and coronary heart disease and headstroke.
The synthetic route of Atorvastatin calcium is using amine ester and diketone as starting material synthetic intermediate condensation product, so at presentAtorvastatin calcium is further synthesized by raw material of intermediate condensate again afterwards, in which: amine ester described in the present patent application fileMolecular formula following reaction formula shown in, be ((4R-cis) -2,2- dimethyl -6- (2- aminoethyl) -1,3- dioxane -4-Tert-butyl acetate) abbreviation;It is ((±)-α-different shown in the molecular formula following reaction formula of diketone described in this paper application documentsBytyry-γ-oxo-N, β-diphenyl -4- fluorobenzene butyramide) abbreviation;Intermediate condensate described in this paper application documentsMolecular formula following reaction formula shown in, be ((4R-cis) -6- [2- [2- (4- fluorophenyl) -5- (1- isopropyl) -3- phenyl -4- [(aniline) carbonyl] -1H- pyrroles -1- base] ethyl] -2,2- dimethyl -1,3- dioxane -4- tert-butyl acetate) and letterClaim, in the prior art composition principle following reaction formula:
The synthetic route of Atorvastatin calcium intermediate condensate is using amine ester and diketone as starting material in the prior artReaction, after reaction, the process steps of intermediate condensate are cumbersome, complicated for operation, the production cycle is long, organic solvent amountConsume that larger, higher cost, yield are low, there are problems that production security.Such as: adding toluene to extract, then through alkali cleaning, pickling, saltWash, then plus active carbon decoloring, then filter activity charcoal, solvent distillation, add ethyl alcohol and n-hexane crystallization, after centrifugal dryingAtorvastatin calcium intermediate condensate, weight yield 110%.
Summary of the invention
To overcome the shortcomings of existing technologies, the present invention provides a kind of preparation methods of Atorvastatin calcium intermediate.It shouldPreparation method is while improving Atorvastatin calcium intermediate yield, the post-processing approach letter of Atorvastatin calcium intermediateRisk when list, operating process simplification, production cycle shortening, organic solvent consumption reduction, production cost reduction, production operationIt reduces.
A kind of preparation method of Atorvastatin calcium intermediate, comprising the following steps:
It 1, is that 1:1-1.5 amine ester and diketone are anti-in in the mixed solvent according to following formulas as starting material using mass ratioIt answers, the mixed solvent is the normal heptane and tetrahydrofuran of volume ratio 1:1-3, every that 5-8ml mixed solvent is added using 1g amine ester;
2,1 gained reaction solution of concentration step removes mixed solvent, obtains Atorvastatin calcium crude intermediate;
3, after the dissolution clarification of 1 ethyl alcohol of recrystallisation solvent being added in step 2 products therefrom, 2 purified water of recrystallisation solvent is added, is droppedTemperature is crystallized to 40-75 DEG C, and preferably 50 DEG C, centrifugal drying is wherein every using just using 3- in 1g amine ester step 3 in step 17ml ethyl alcohol and 1-4ml purified water, preferably 4ml ethyl alcohol and 3ml purified water.
A kind of preparation method of Atorvastatin calcium intermediate, wherein the mass ratio of the amine ester and diketone is 1:1-1.25。
A kind of preparation method of Atorvastatin calcium intermediate, wherein the mixed solvent be volume ratio 1:2-2.5 justHeptane and tetrahydrofuran.
A kind of preparation method of Atorvastatin calcium intermediate, it is wherein every mixed using 1g amine ester addition 6-7.5ml in step 1Bonding solvent.
A kind of preparation method of Atorvastatin calcium intermediate, wherein the condition of reaction described in step 1 is to be heated to refluxReact 30-50h, preferably 36-40h.
Compared with prior art, the invention has the following beneficial effects:
1, no longer extraction, alkali cleaning, pickling and salt are washed in step, simplify production procedure, shorten the production cycle, are reducedThe consumption and sewage discharge of organic solvent, realize clean manufacturing, and risk when production operation reduces;
2, pass through amine ester and diketone special ratios, mixed solvent specific composition, recrystallisation solvent specific composition, crystallization temperature etc.The selection of condition makes 125% or more the weight yield of product Atorvastatin calcium intermediate condensate, the HPLC purity of productIt is 99.0%, the weight yield of product improves 15% or more, and cost is greatly lowered.
Detailed description of the invention
Fig. 1 is the flow chart of the preparation method of Atorvastatin calcium intermediate of the present invention.
Specific embodiment
With reference to the accompanying drawing, specific embodiments of the present invention will be described in detail, it is to be understood that guarantor of the inventionShield range is not limited by the specific implementation.
Embodiment 1
Amine ester 16g and diketone 20g is added in 250ml reaction flask and is dissolved in 34ml normal heptane and 68ml tetrahydrofuran groupAt in the mixed solvent, temperature rising reflux react 40 hours, after completion of the reaction concentration of reaction solution remove mixed solvent, obtain atropic and cut downStatin calcium crude intermediate is added purified water 64ml, is cooled to 50 DEG C after adding 110ml ethyl alcohol to make crude intermediate dissolution clarificationMaterial is precipitated, centrifugal filtration obtains intermediate 25.1g, and the weight yield relative to diketone is that 125.5%, HPLC purity is99.0%.
Embodiment 2
Amine ester 16g and diketone 20g is added in 250ml reaction flask and is dissolved in 34ml normal heptane and 85ml tetrahydrofuran groupAt in the mixed solvent, temperature rising reflux react 36 hours, after completion of the reaction concentration of reaction solution remove mixed solvent, obtain atropic and cut downAfter adding 64ml ethyl alcohol to make crude intermediate dissolution clarification purified water 48ml is added, being cooled to 75 DEG C makes in statin calcium crude intermediateMaterial is precipitated, and centrifugal filtration obtains intermediate condensate 25.3g, and relative to the weight yield 126.5% of diketone, HPLC purity is99.0%.
Embodiment 3
Amine ester 16g and diketone 24g is added in 250ml reaction flask and is dissolved in 34ml normal heptane and 85ml tetrahydrofuran groupAt in the mixed solvent, temperature rising reflux react 50 hours, after completion of the reaction concentration of reaction solution remove mixed solvent, obtain atropic and cut downAfter adding 80ml ethyl alcohol to make crude intermediate dissolution clarification purified water 32ml is added, being cooled to 70 DEG C makes in statin calcium crude intermediateMaterial is precipitated, and centrifugal filtration obtains intermediate condensate 25.2g, and relative to the weight yield 126.0% of diketone, HPLC purity is99.0%.
Embodiment 4
Amine ester 16g and diketone 20g is added in 250ml reaction flask and is dissolved in 38ml normal heptane and 76ml tetrahydrofuran groupAt in the mixed solvent, temperature rising reflux react 40 hours, after completion of the reaction concentration of reaction solution remove mixed solvent, obtain atropic and cut downAfter adding 64ml ethyl alcohol to make crude intermediate dissolution clarification purified water 48ml is added, being cooled to 50 DEG C makes in statin calcium crude intermediateMaterial is precipitated, and centrifugal filtration obtains intermediate condensate 26.6g, and relative to the weight yield 133.0% of diketone, HPLC purity is99.0%.
Disclosed above is only specific embodiments of the present invention, and still, the present invention is not limited to this, any this fieldWhat technical staff can think variation should all fall into protection scope of the present invention.

Claims (7)

CN201610004301.0A2016-01-052016-01-05A kind of preparation method of Atorvastatin calcium intermediateActiveCN106938996B (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN201610004301.0ACN106938996B (en)2016-01-052016-01-05A kind of preparation method of Atorvastatin calcium intermediate

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN201610004301.0ACN106938996B (en)2016-01-052016-01-05A kind of preparation method of Atorvastatin calcium intermediate

Publications (2)

Publication NumberPublication Date
CN106938996A CN106938996A (en)2017-07-11
CN106938996Btrue CN106938996B (en)2019-11-19

Family

ID=59468485

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN201610004301.0AActiveCN106938996B (en)2016-01-052016-01-05A kind of preparation method of Atorvastatin calcium intermediate

Country Status (1)

CountryLink
CN (1)CN106938996B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN108218759B (en)*2018-01-122021-01-01天方药业有限公司Preparation method of atorvastatin calcium
CN109232353A (en)*2018-10-092019-01-18河南师范大学A kind of preparation method of Atorvastatin calcium condensation product

Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2003024959A1 (en)*2001-09-142003-03-27EGIS Gyógyszergyár Rt.Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin
WO2007088553A1 (en)*2006-01-312007-08-09Jubilant Organosys LimitedProcess for the preparation of amorphous atorvastatin calcium salt
EP2075246A1 (en)*2007-12-272009-07-01M. J. Institute of ResearchA process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN102344401A (en)*2011-09-152012-02-08景德镇市富祥药业有限公司Method for preparing amorphous atorvastatin calcium
CN102766136A (en)*2012-08-072012-11-07浙江宏元药业有限公司Method for preparing atorvastatin calcium intermediate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2003024959A1 (en)*2001-09-142003-03-27EGIS Gyógyszergyár Rt.Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin
WO2007088553A1 (en)*2006-01-312007-08-09Jubilant Organosys LimitedProcess for the preparation of amorphous atorvastatin calcium salt
EP2075246A1 (en)*2007-12-272009-07-01M. J. Institute of ResearchA process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN102344401A (en)*2011-09-152012-02-08景德镇市富祥药业有限公司Method for preparing amorphous atorvastatin calcium
CN102766136A (en)*2012-08-072012-11-07浙江宏元药业有限公司Method for preparing atorvastatin calcium intermediate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Paal-Knorr反应合成2,5-二甲基吡咯衍生物;王芬华,等;《安徽工程大学学报》;20140630;第29卷(第2期);第26-30页*

Also Published As

Publication numberPublication date
CN106938996A (en)2017-07-11

Similar Documents

PublicationPublication DateTitle
Donelson et al.An efficient one-pot synthesis of polyhydroquinoline derivatives through the Hantzsch four component condensation
JP3510253B2 (en) Novel process for the preparation of trans-6- [2- (substituted-pyrrol-1-yl) alkyl] pyran-2-one inhibitors of cholesterol synthesis
FI120344B (en) A process for the preparation of atorvastatin calcium in amorphous form
CN1543468A (en)Processes for preparing calcium salt forms of statins
CN106938996B (en)A kind of preparation method of Atorvastatin calcium intermediate
CN108218759B (en)Preparation method of atorvastatin calcium
Mallinger et al.3-Aryltetronic acids: efficient preparation and use as precursors for vulpinic acids
CN102344401A (en)Method for preparing amorphous atorvastatin calcium
EP2075246A1 (en)A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN100503564C (en) Preparation method of high-purity crystalline atorvastatin sodium
EP1853558A1 (en)Process for producing atorvastatin hemicalcium
WO2007088553A1 (en)Process for the preparation of amorphous atorvastatin calcium salt
CN102858740B (en)The preparation of the atorvastatin of low lactone impurity
CN110563628A (en)Crystallization method for preparing high-purity and monodisperse I crystal form atorvastatin calcium by double kettles
CN101492406A (en)Method for preparing amorphous atorvastatin calcium
CN109293548A (en) A kind of preparation method of high-quality HMG-CoA reductase inhibitor atorvastatin calcium
CN101429195A (en)Process for producing important synthesis midbody of high purity atorvastatin
CN1946687A (en) Polymorphic form of atorvastatin tert-butyl ester and its use as an intermediate in the preparation of atorvastatin
JPH07309862A (en)Production of lactide
CN110668990A (en) A kind of single kettle prepares the crystallization method of high-purity monodisperse I crystal form atorvastatin calcium
CN112409182A (en)Synthesis, purification and separation method of menthyl lactate
CN104292201A (en)Method for preparing 3-ester group catechin
CN114181188B (en)Non-solvation synthesis method of atorvastatin calcium intermediate
EP2373609A1 (en)Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
Pramanik et al.Visible light induced Biginelli reaction in fruit juice medium: A green strategy for synthesis of pharmaceutically active Dihydropyrimidinones

Legal Events

DateCodeTitleDescription
PB01Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination
GR01Patent grant
GR01Patent grant

[8]ページ先頭

©2009-2025 Movatter.jp